Pathology Unit, Fondazione IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG), Italy.
Department of Public Health, University of Naples Federico II, Naples (NA), Italy.
J Clin Pathol. 2023 Jul;76(7):492-496. doi: 10.1136/jclinpath-2022-208143. Epub 2022 Feb 10.
Mucinous adenocarcinoma (MA) is associated with a high frequency of microsatellite instability (MSI). In the metastatic setting, it is crucial to establish mismatch repair (MMR) and/or MSI status. However, genetic heterogeneity between primary tumour and synchronous metastasis and the diagnostic accuracy of the assay may hamper the MMR/MSI status evaluation.
In this study, we assessed the concordance rate of the MMR/MSI status between primary tumour and paired synchronous metastasis of 25 MAs. MMR status was evaluated by immunohistochemistry (IHC), while MSI status was evaluated by using three different molecular approaches: microfluidic electrophoresis of PCR products (TapeStation 4200 platform), full-closed RTqPCR system (Idylla system) and multiplex amplification with fluorescent primers and subsequent DNA fragment analysis on an automated sequencer (Titano MSI test).
The concordance rate between primary MA and metastasis was 21/21 (100%), 23/25 (92.0%), 23/25 (92.0%) and 21/25 (84%) by using IHC, Idylla system, Titano MSI test and TapeStation 4200 system. All the four methods used in our study displayed high concordant rate, ranging from 91.0% (IHC vs Tapestation 4200 platform) to 98.0% (IHC vs Titano).
Several methodologies are frequently adopted in routine practice to successfully perform MMR/MSI status analysis. The most relevant issues related to MMR/MSI status analysis in MAs concern with low percentage of neoplastic cell and abundant mucine that may affect the molecular analysis. Thus, it might be useful to acquire both primary and metastatic sample to evaluate the MMR/MSI status by integrating IHC evaluation and molecular methodologies to successfully perform molecular profiling for MA patients.
黏液性腺癌(MA)与微卫星不稳定性(MSI)的频率高相关。在转移背景下,确定错配修复(MMR)和/或 MSI 状态至关重要。然而,原发肿瘤和同步转移之间的遗传异质性以及检测方法的诊断准确性可能会阻碍 MMR/MSI 状态的评估。
本研究评估了 25 例 MA 患者的原发肿瘤和配对同步转移之间 MMR/MSI 状态的一致性率。通过免疫组织化学(IHC)评估 MMR 状态,同时使用三种不同的分子方法评估 MSI 状态:PCR 产物的微流电泳(TapeStation 4200 平台)、全封闭 RTqPCR 系统(Idylla 系统)和使用荧光引物的多重扩增以及随后在自动测序仪上进行 DNA 片段分析(Titano MSI 测试)。
使用 IHC、Idylla 系统、Titano MSI 测试和 TapeStation 4200 系统,原发 MA 与转移瘤之间的一致性率分别为 21/21(100%)、23/25(92.0%)、23/25(92.0%)和 21/25(84%)。我们研究中使用的所有四种方法均显示出高一致性率,范围从 91.0%(IHC 与 TapeStation 4200 平台)到 98.0%(IHC 与 Titano)。
在常规实践中,常采用几种方法来成功进行 MMR/MSI 状态分析。在 MA 中与 MMR/MSI 状态分析相关的最主要问题是肿瘤细胞的比例低和大量黏液,这可能会影响分子分析。因此,获取原发和转移样本以通过整合 IHC 评估和分子方法来评估 MMR/MSI 状态,对于成功对 MA 患者进行分子谱分析可能是有用的。